Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
The present invention provides methods for treating or preventing cancer by administering an anticancer agent and an antigen-binding molecule comprising a domain that binds to a molecule expressed on the surface of a cell having an immune response-suppressing function and a T cell receptor complex-binding domain. The present invention also provides pharmaceutical compositions for treating or preventing cancer, each comprising a combination of the anticancer agent and the antigen-binding molecule.
1. A method for treating colorectal cancer comprising administering to an individual in need thereof an effective amount of gemcitabine and an effective amount of an anti-CTLA4/CD3 bispecific antibody that comprises:
(1) a first half that binds to CTLA4 and comprises a heavy chain variable region of SEQ ID NO: 28, a light chain variable region of SEQ ID NO: 29, a heavy chain constant region of SEQ ID NO: 53 and a light chain constant region of SEQ ID NO: 31; and
(2) a second half that binds to CD3 and comprises a heavy chain variable region of SEQ ID NO: 35, a light chain variable region of SEQ ID NO: 36, a heavy chain constant region of SEQ ID NO: 54 and a light chain constant region of SEQ ID NO: 31,
wherein gemcitabine is administered at a dose of 120 mg/kg and the anti-CTLA4/CD3 bispecific antibody is administered at a dose corresponding to 25 μg/mouse intravenously.
2. A method for treating non-small-cell lung cancer comprising administering to an individual in need thereof an effective amount of an anti-CTLA4/CD3 bispecific antibody and an effective amount of and anti-GPC3/CD3 bispecific antibody,
wherein the anti-CTLA4/CD3 bispecific antibody comprises:
(1) a first half that binds to CTLA4 and comprises a heavy chain variable region of SEQ ID NO: 28, a light chain variable region of SEQ ID NO: 29, a heavy chain constant region of SEQ ID NO: 53 and a light chain constant region of SEQ ID NO: 31; and
(2) a second half that binds to CD3 and comprises a heavy chain variable region of SEQ ID NO: 35, a light chain variable region of SEQ ID NO: 36, a heavy chain constant region of SEQ ID NO: 54 and a light chain constant region of SEQ ID NO: 31,
wherein the anti-GPC3/CD3 bispecific antibody comprises:
(3) a first half that binds to GPC3 and comprises a heavy chain variable region of SEQ ID NO: 55, a light chain variable region of SEQ ID NO: 56, a heavy chain constant region of SEQ ID NO: 53 and a light chain constant region of SEQ ID NO: 31; and
(4) a second half that binds to CD3 and comprises a heavy chain variable region of SEQ ID NO: 35, a light chain variable region of SEQ ID NO: 36, a heavy chain constant region of SEQ ID NO: 54 and a light chain constant region of SEQ ID NO: 31,
wherein the anti-CTLA4/CD3 bispecific antibody and the anti-GPC3/CD3 bispecific antibody are administered each at a dose corresponding to 100 μg/mouse intravenously.